Armenian SH, et al. - Given the association of sarcopenia (low muscle mass) with physical disability and premature mortality in individuals with nonmalignant diseases, researchers investigated if it predicts nonrelapse mortality (NRM) and poor overall survival in patients undergoing hematopoietic cell transplantation (HCT). Outcomes of this retrospective cohort study of 859 patients with acute leukemia or myelodysplastic syndrome who underwent a first HCT as adults (≥18 years) suggested the significance and independent predictive value of sarcopenia for survival after HCT. It had potential additional downstream impacts on health-economic outcomes. This information may assist in treatment decisions prior to HCT and guide interventions to reduce the risk of treatment-related complications after HCT.